TRIKAFTA (COPACKAGED) · pharmadog

Sign In Subscribe

TRIKAFTA (COPACKAGED) · pharmadog

Patent cliff

source: FDA Orange Book

first barrier falls

Oct 21, 2026

106 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (127)

Jul 17, 2038method-of-use (U-4220)US 12350262
Jul 17, 2038method-of-use (U-4221)US 12350262
Jul 17, 2038method-of-use (U-4222)US 12350262
Dec 8, 2037compositionUS 10793547
Dec 8, 2037compositionUS 10793547
Dec 8, 2037compositionUS 10793547
Dec 8, 2037compositionUS 10793547
Dec 8, 2037formulationUS 11179367
Dec 8, 2037formulationUS 11179367
Dec 8, 2037formulationUS 11179367
Dec 8, 2037formulationUS 11179367
Dec 8, 2037compositionUS 11453655
Dec 8, 2037compositionUS 11453655
Dec 8, 2037compositionUS 11453655
Dec 8, 2037compositionUS 11453655
Dec 8, 2037formulationUS 11517564
Dec 8, 2037formulationUS 11517564
Dec 8, 2037formulationUS 11517564
Dec 8, 2037formulationUS 11517564
Oct 6, 2035compositionUS 10758534
Oct 6, 2035compositionUS 10758534
Oct 6, 2035compositionUS 10758534
Oct 6, 2035compositionUS 10758534
Oct 6, 2035compositionUS 11426407
Oct 6, 2035compositionUS 11426407
Oct 6, 2035compositionUS 11426407
Oct 6, 2035compositionUS 11426407
Jul 15, 2033method-of-use (U-3154)US 9012496
Jul 15, 2033method-of-use (U-3154)US 9012496
Feb 27, 2033formulationUS 10272046
Feb 27, 2033formulationUS 10272046
Feb 27, 2033formulationUS 11147770
Feb 27, 2033formulationUS 11147770
Feb 27, 2033formulationUS 11752106
Feb 27, 2033formulationUS 11752106
Feb 27, 2033formulationUS 12214083
Feb 27, 2033formulationUS 12214083
Feb 27, 2033formulationUS 8883206
Feb 27, 2033formulationUS 8883206
Jul 10, 2031compositionUS RE50453
Jul 10, 2031compositionUS RE50453
Jul 10, 2031compositionUS RE50453
Jul 10, 2031compositionUS RE50453
Mar 25, 2031formulationUS 100816214.7y
Mar 25, 2031formulationUS 100816214.7y
Mar 25, 2031formulationUS 100816214.7y
Mar 25, 2031formulationUS 100816214.7y
Mar 25, 2031formulationUS 115780624.7y
Mar 25, 2031formulationUS 115780624.7y
Mar 25, 2031formulationUS 115780624.7y
Mar 25, 2031formulationUS 115780624.7y
Aug 13, 2029formulationUS 106464813.1y
Aug 13, 2029formulationUS 106464813.1y
Aug 13, 2029formulationUS 106464813.1y
Aug 13, 2029formulationUS 106464813.1y
Aug 13, 2029method-of-use (U-4055)US 115649163.1y
Aug 13, 2029method-of-use (U-4063)US 115649163.1y
Aug 13, 2029method-of-use (U-4063)US 115649163.1y
Aug 13, 2029method-of-use (U-4055)US 115649163.1y
Aug 13, 2029formulationUS 124586353.1y
Aug 13, 2029formulationUS 124586353.1y
Aug 13, 2029formulationUS 124586353.1y
Aug 13, 2029formulationUS 124586353.1y
Nov 12, 2027method-of-use (U-4066)US 84153871.4y
Nov 12, 2027method-of-use (U-3144)US 84153871.4y
Nov 12, 2027method-of-use (U-4066)US 84153871.4y
Nov 12, 2027method-of-use (U-3144)US 84153871.4y
Aug 5, 2027method-of-use (U-3144)US 83242421.1y
Aug 5, 2027method-of-use (U-3144)US 83242421.1y
Aug 5, 2027method-of-use (U-3589)US 83242421.1y
Aug 5, 2027method-of-use (U-3589)US 83242421.1y
Jun 3, 2027compositionUS 7776905331d
Jun 3, 2027compositionUS 7776905331d
Jun 3, 2027compositionUS 7776905331d
Jun 3, 2027compositionUS 7776905331d
May 20, 2027compositionUS 7495103317d
May 20, 2027compositionUS 7495103317d
May 20, 2027compositionUS 7495103317d
May 20, 2027compositionUS 7495103317d
May 1, 2027compositionUS 7645789298d
May 1, 2027compositionUS 7645789298d
May 1, 2027compositionUS 7645789298d
May 1, 2027compositionUS 7645789298d
May 1, 2027method-of-use (U-3589)US 8598181298d
May 1, 2027method-of-use (U-4056)US 8598181298d
May 1, 2027method-of-use (U-4056)US 8598181298d
May 1, 2027method-of-use (U-3589)US 8598181298d
May 1, 2027compositionUS 8623905298d
May 1, 2027compositionUS 8623905298d
May 1, 2027compositionUS 8623905298d
May 1, 2027compositionUS 8623905298d
Apr 9, 2027formulationUS 10022352276d
Apr 9, 2027formulationUS 10022352276d
Apr 9, 2027formulationUS 10022352276d
Apr 9, 2027formulationUS 10022352276d
Apr 9, 2027compositionUS 10239867276d
Apr 9, 2027compositionUS 10239867276d
Apr 9, 2027compositionUS 10239867276d
Apr 9, 2027compositionUS 10239867276d
Apr 9, 2027compositionUS 11639347276d
Apr 9, 2027compositionUS 11639347276d
Apr 9, 2027compositionUS 11639347276d
Apr 9, 2027compositionUS 11639347276d
Apr 9, 2027formulationUS 9974781276d
Apr 9, 2027formulationUS 9974781276d
Apr 9, 2027formulationUS 9974781276d
Apr 9, 2027formulationUS 9974781276d
Dec 28, 2026formulationUS 8410274174d
Dec 28, 2026formulationUS 8410274174d
Dec 28, 2026formulationUS 8410274174d
Dec 28, 2026formulationUS 8410274174d
Dec 28, 2026compositionUS 8754224174d
Dec 28, 2026compositionUS 8754224174d
Dec 28, 2026compositionUS 8754224174d
Dec 28, 2026compositionUS 8754224174d
Dec 28, 2026formulationUS 9670163174d
Dec 28, 2026formulationUS 9670163174d
Dec 28, 2026formulationUS 9670163174d
Dec 28, 2026formulationUS 9670163174d
Dec 28, 2026formulationUS 9931334174d
Dec 28, 2026formulationUS 9931334174d
Dec 28, 2026formulationUS 9931334174d
Dec 28, 2026formulationUS 9931334174d
Jul 6, 2026method-of-use (U-3593)US 8354427
Jul 6, 2026method-of-use (U-3145)US 8354427
Jul 6, 2026method-of-use (U-3145)US 8354427
Jul 6, 2026method-of-use (U-3593)US 8354427

FDA exclusivities (17)

Dec 20, 2031ODE-512Orphan Drug (7y)
Dec 20, 2031ODE-512Orphan Drug (7y)
Dec 20, 2031ODE-512Orphan Drug (7y)
Dec 20, 2031ODE-512Orphan Drug (7y)
Apr 26, 2030ODE-433Orphan Drug (7y)3.8y
Apr 26, 2030ODE-433Orphan Drug (7y)3.8y
Jun 8, 2028ODE-357Orphan Drug (7y)